ログイン

15. COMPLEMENT SYSTEM

15. COMPLEMENT SYSTEM
76問 • 2年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Series of more than 30 soluble and cell-bound proteins (proteinases)that interact in a very specific way to enhance host defense mechanisms.

    COMPLEMENT SYSTEM

  • 2

    nature of complement DISCOVERED BY:

    Jules Bordet

  • 3

    COMPLEMENT SYSTEM Production: MOST ARE PRODUCED in the ________

    LIVER

  • 4

    Functions: a. Opsonization

    COMPLEMENT SYSTEM

  • 5

    Functions: Cell lysis (end product of Complement)

    COMPLEMENT SYSTEM

  • 6

    Functions: Inflammation (via anaphylotoxin)

    COMPLEMENT SYSTEM

  • 7

    Inflammation (via ? )

    anaphylotoxin

  • 8

    (end product of Complement)

    Cell lysis

  • 9

    Functions: Chemotaxis

    COMPLEMENT SYSTEM

  • 10

    Functions: NOT A VIRAL

    COMPLEMENT SYSTEM

  • 11

    Classical  Triggered by:

    Ag-Ab complex

  • 12

    Triggered by: Ag-Ab complex

    Classical

  • 13

    MOST EFFICIENT TO FIX COMPLEMENT

    Ab: IgM

  • 14

    HOW MANY IgM – IN CLASSICAL PATHWAY

    ONE

  • 15

    IgG – must be at least ?

    two

  • 16

    – must be at least two

    IgG

  • 17

    CAUSES GENERATION OF PLASMIN TO ACTIVATE COMPLEMENT; TRIGGER BY PRODUCING PLASMIN

    Hageman Coag factor

  • 18

    Classical Additional initiator

    CRP, mycoplasma AND E COLI

  • 19

    Classical 3 Main Stages

    Recognition Activation/ Amplification MAC (membrane attack complex)

  • 20

    MAC (membrane attack complex)

    C5-C9

  • 21

    C5-C9

    MAC (membrane attack complex)

  • 22

    Recognition –

    C1 (C1qrs)

  • 23

    what site? – C1 (C1qrs)

    Recognition

  • 24

    C1- ________ complement, stabilized by ________

    HEAVIEST; CALCIUM + MG

  • 25

    - HEAVIEST complement, stabilized by CALCIUM + MG

    C1

  • 26

    C1q – recognizes ________ of two Adjacent Ab

    FC

  • 27

    – recognizes FC of two Adjacent Ab

    C1q

  • 28

    – zymogens; INACTIVE

    C1rs

  • 29

    Activation/ Amplification –

    C4, C2, and C3

  • 30

    – C4, C2, and C3

    Activation/ Amplification

  • 31

    – SECOND most abundant complement in classical pathway

    C4

  • 32

    C4b- 1st ________ step

    AMPLIFICATION

  • 33

    - 1st AMPLIFICATION step

    C4b

  • 34

    C4b2a –

    C3 convertase

  • 35

    in Classical pathway– C3 convertase

    C4b2a

  • 36

    – MAJOR constituent of the complement system

    C3

  • 37

    PIVOTAL point for all 3 pathways

    C3

  • 38

    is the most SIGNIFICANT step in the entire process in alternative pathway

    cleavage of C3 to C3b

  • 39

    represents a SECOND and major amplification process

    Cleavage of C3

  • 40

    C4b2a3b – C5 convertase, ________ step in the formation of the activation unit.

    LAST

  • 41

    – C5 convertase, LAST step in the formation of the activation unit in classical pathway

    C4b2a3b

  • 42

    C4b2a3b – ?, LAST step in the formation of the activation unit.

    C5 convertase

  • 43

    the beginning of MAC

    C5b

  • 44

    Splitting of C3 and C5 represents the most significant biological consequences of the complement system

    MAC (membrane attack complex)

  • 45

    - starts pore formation

    C8

  • 46

    – tubular pore that causes cell lysis to nucleated cells. Last stage of MAC

    C9

  • 47

    MAC 2 Mechanisms

    Channel formation Binding of phospholipids

  • 48

    –MOST POTENT and also a chemotaxin

    C5a

  • 49

    – Least effective anaphylatoxins

    C4a

  • 50

    – kinin-like activity

    C2b

  • 51

    – powerful opsonin

    C3b and C4b

  • 52

    Non-Ab-initiated pathway

    Alternative (Properdin)

  • 53

    described by Pillemer

    Alternative (Properdin)

  • 54

    Alternative (Properdin) described by

    Pillemer

  • 55

    Triggered by: Bacterial cell wall: LPS, fungal cell wall (zymosan), yeast, virus, virally infected cells, tumor cell lines, and parasites (trypanosomes); Aggregated IgG2, IgA, and IgE; In PNH –triggered by RBC ->Lysis

    Alternative (Properdin)

  • 56

    Alternative (Properdin) Triggered by: ?

    Bacterial cell wall: LPS

  • 57

    pathway which is Innate Immunity

    Alternative (Properdin)

  • 58

    –was the 1st protein to function in Alternative

    Properdin

  • 59

    – major CONTROLLING event in ALTERNATIVE PATHWAY

    Factor H

  • 60

    Factor D -> Cleaves

    Factor B

  • 61

    -> Cleaves Factor B

    Factor D

  • 62

    C3 is continuously hydrolyzed by water -> C3b + Factor B = ________

    C3bBb

  • 63

    C3 is continuously hydrolyzed by water -> C3b + Factor B = C3bBb + P = C3bBbP -> cleaves more C3 = ______ -> has high affinity for C5 -> beginning of MAC

    C3bBb3b

  • 64

    ? -> STABILIZE C3 convertase in alternative pathway

    Properdin

  • 65

    ALTERNATIVE PATHWAY Properdin -> STABILIZE ?

    C3 convertase

  • 66

    Lowest concentration among complement proteins

    Alternative (Properdin)

  • 67

    Triggered by: recognition of carbohydrate on microbial cell wall

    MBL (lectin)

  • 68

    OUR PROTECTION WHEN WE ARE STILL A BABY

    lectin

  • 69

    MBL (lectin) is dependent in

    CALCIUM DEPENDENT

  • 70

    – proteins that bind to carbohydrates

    Lectins

  • 71

    – binds to mannose. Is considered acute phase reactant.

    MBL (mannose-binding lectin)

  • 72

    MBL (mannose-binding lectin) – binds to mannose. Is considered ?.

    acute phase reactant

  • 73

    MBL (lectin) Production:

    Liver

  • 74

    Infant defense mechanism

    MBL (lectin)

  • 75

    deficiency of MBL

    neonatal pneumonia and sepsis.

  • 76

    MBL (lectin) - unclear

    MASP 1 and MASP 3

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Series of more than 30 soluble and cell-bound proteins (proteinases)that interact in a very specific way to enhance host defense mechanisms.

    COMPLEMENT SYSTEM

  • 2

    nature of complement DISCOVERED BY:

    Jules Bordet

  • 3

    COMPLEMENT SYSTEM Production: MOST ARE PRODUCED in the ________

    LIVER

  • 4

    Functions: a. Opsonization

    COMPLEMENT SYSTEM

  • 5

    Functions: Cell lysis (end product of Complement)

    COMPLEMENT SYSTEM

  • 6

    Functions: Inflammation (via anaphylotoxin)

    COMPLEMENT SYSTEM

  • 7

    Inflammation (via ? )

    anaphylotoxin

  • 8

    (end product of Complement)

    Cell lysis

  • 9

    Functions: Chemotaxis

    COMPLEMENT SYSTEM

  • 10

    Functions: NOT A VIRAL

    COMPLEMENT SYSTEM

  • 11

    Classical  Triggered by:

    Ag-Ab complex

  • 12

    Triggered by: Ag-Ab complex

    Classical

  • 13

    MOST EFFICIENT TO FIX COMPLEMENT

    Ab: IgM

  • 14

    HOW MANY IgM – IN CLASSICAL PATHWAY

    ONE

  • 15

    IgG – must be at least ?

    two

  • 16

    – must be at least two

    IgG

  • 17

    CAUSES GENERATION OF PLASMIN TO ACTIVATE COMPLEMENT; TRIGGER BY PRODUCING PLASMIN

    Hageman Coag factor

  • 18

    Classical Additional initiator

    CRP, mycoplasma AND E COLI

  • 19

    Classical 3 Main Stages

    Recognition Activation/ Amplification MAC (membrane attack complex)

  • 20

    MAC (membrane attack complex)

    C5-C9

  • 21

    C5-C9

    MAC (membrane attack complex)

  • 22

    Recognition –

    C1 (C1qrs)

  • 23

    what site? – C1 (C1qrs)

    Recognition

  • 24

    C1- ________ complement, stabilized by ________

    HEAVIEST; CALCIUM + MG

  • 25

    - HEAVIEST complement, stabilized by CALCIUM + MG

    C1

  • 26

    C1q – recognizes ________ of two Adjacent Ab

    FC

  • 27

    – recognizes FC of two Adjacent Ab

    C1q

  • 28

    – zymogens; INACTIVE

    C1rs

  • 29

    Activation/ Amplification –

    C4, C2, and C3

  • 30

    – C4, C2, and C3

    Activation/ Amplification

  • 31

    – SECOND most abundant complement in classical pathway

    C4

  • 32

    C4b- 1st ________ step

    AMPLIFICATION

  • 33

    - 1st AMPLIFICATION step

    C4b

  • 34

    C4b2a –

    C3 convertase

  • 35

    in Classical pathway– C3 convertase

    C4b2a

  • 36

    – MAJOR constituent of the complement system

    C3

  • 37

    PIVOTAL point for all 3 pathways

    C3

  • 38

    is the most SIGNIFICANT step in the entire process in alternative pathway

    cleavage of C3 to C3b

  • 39

    represents a SECOND and major amplification process

    Cleavage of C3

  • 40

    C4b2a3b – C5 convertase, ________ step in the formation of the activation unit.

    LAST

  • 41

    – C5 convertase, LAST step in the formation of the activation unit in classical pathway

    C4b2a3b

  • 42

    C4b2a3b – ?, LAST step in the formation of the activation unit.

    C5 convertase

  • 43

    the beginning of MAC

    C5b

  • 44

    Splitting of C3 and C5 represents the most significant biological consequences of the complement system

    MAC (membrane attack complex)

  • 45

    - starts pore formation

    C8

  • 46

    – tubular pore that causes cell lysis to nucleated cells. Last stage of MAC

    C9

  • 47

    MAC 2 Mechanisms

    Channel formation Binding of phospholipids

  • 48

    –MOST POTENT and also a chemotaxin

    C5a

  • 49

    – Least effective anaphylatoxins

    C4a

  • 50

    – kinin-like activity

    C2b

  • 51

    – powerful opsonin

    C3b and C4b

  • 52

    Non-Ab-initiated pathway

    Alternative (Properdin)

  • 53

    described by Pillemer

    Alternative (Properdin)

  • 54

    Alternative (Properdin) described by

    Pillemer

  • 55

    Triggered by: Bacterial cell wall: LPS, fungal cell wall (zymosan), yeast, virus, virally infected cells, tumor cell lines, and parasites (trypanosomes); Aggregated IgG2, IgA, and IgE; In PNH –triggered by RBC ->Lysis

    Alternative (Properdin)

  • 56

    Alternative (Properdin) Triggered by: ?

    Bacterial cell wall: LPS

  • 57

    pathway which is Innate Immunity

    Alternative (Properdin)

  • 58

    –was the 1st protein to function in Alternative

    Properdin

  • 59

    – major CONTROLLING event in ALTERNATIVE PATHWAY

    Factor H

  • 60

    Factor D -> Cleaves

    Factor B

  • 61

    -> Cleaves Factor B

    Factor D

  • 62

    C3 is continuously hydrolyzed by water -> C3b + Factor B = ________

    C3bBb

  • 63

    C3 is continuously hydrolyzed by water -> C3b + Factor B = C3bBb + P = C3bBbP -> cleaves more C3 = ______ -> has high affinity for C5 -> beginning of MAC

    C3bBb3b

  • 64

    ? -> STABILIZE C3 convertase in alternative pathway

    Properdin

  • 65

    ALTERNATIVE PATHWAY Properdin -> STABILIZE ?

    C3 convertase

  • 66

    Lowest concentration among complement proteins

    Alternative (Properdin)

  • 67

    Triggered by: recognition of carbohydrate on microbial cell wall

    MBL (lectin)

  • 68

    OUR PROTECTION WHEN WE ARE STILL A BABY

    lectin

  • 69

    MBL (lectin) is dependent in

    CALCIUM DEPENDENT

  • 70

    – proteins that bind to carbohydrates

    Lectins

  • 71

    – binds to mannose. Is considered acute phase reactant.

    MBL (mannose-binding lectin)

  • 72

    MBL (mannose-binding lectin) – binds to mannose. Is considered ?.

    acute phase reactant

  • 73

    MBL (lectin) Production:

    Liver

  • 74

    Infant defense mechanism

    MBL (lectin)

  • 75

    deficiency of MBL

    neonatal pneumonia and sepsis.

  • 76

    MBL (lectin) - unclear

    MASP 1 and MASP 3